Xalatan®
XALATAN is an ocular hypotensive agent that is believed to reduce
intraocular pressure (IOP) by increasing uveoscleral outflow. An estimated 100
million prescriptions for XALATAN have been written worldwide* and it is the most
prescribed IOP-lowering agent in the United States. XALATAN is indicated for
the reduction of elevated intraocular pressure (IOP) in patients with open-angle
glaucoma or ocular hypertension. XALATAN has a potent and long-acting IOP-lowering
effect without significant long-term drift. Studies showed that XALATAN effectively
reduced IOP 24% to 33% in patients with open-angle glaucoma and ocular hypertension.
The optimal clinical effect of XALATAN is achieved with daily topical administration.
Once-daily administration can enhance patient convenience. Studies show that after
2 years of treatment, XALATAN maintained IOP reduction at the same level with
no indication of rising. After 2 years of treatment, only 7% of patients required
either additional medication or a switch from XALATAN because of insufficient
IOP control (Meta-analysis of three 6-month double-masked trials with 2 open-label
extensions in patients with open-angle glaucoma or ocular hypertension treated
with XALATAN gd or timolol maleate 0.5% bid for 6 months, then with XALATAN up
to 2 years; N= 779 at baseline, n= 113 at 2 years). Order
Xalatan XALATAN is more effective than a combination of timolol plus
pilocarpine3 and at least as effective as timolol plus dorzolamide in open-label
studies,4,5 indicating that a switch to XALATAN monotherapy can be considered
before beginning combination therapy in patients inadequately controlled on beta-adrenergic
antagonists. XALATAN can be used concomitantly with other topical ophthalmic agents
to lower IOP. If more than one topical agent is used, administer at least 5 minutes
apart. XALATAN has minimal systemic side effects. There are no cardiopulmonary
contraindications and no statistically significant effects on heart rate or systolic
or diastolic pressure associated with XALATAN. XALATAN has no established association
with depression, impotence, or nausea.28, 29 XALATAN can cause changes
to pigmented tissues. Most frequently reported are increased pigmentation of the
iris, periorbital tissue (eyelid), and eyelashes, and growth of eyelashes. Pigmentation
is expected to increase as long as XALATAN is administered; these changes are
likely to be permanent and the effects beyond 5 years are not known. Most
common ocular event/signs and symptoms (5% to 15%): blurred vision, burning and
stinging, conjunctival hyperemia, foreign body sensation, itching, increased iris
pigmentation, and punctate epithelial keratopathy. XALATAN should be used
with caution in patients with a history of intraocular inflammation (iritis/uveitis)
and should generally not be used in patients with active intraocular inflammation.
XALATAN should be used with caution in aphakic patients, in pseudophakic patients
with a torn posterior lens capsule, or in patients with known risk factors for
macular edema. Order
Xalatan Xalatan®
Search for other medications starting with A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
| 
